# Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2

> **NCT04626089** · PHASE2 · WITHDRAWN · sponsor: **Laboratorios Silanes S.A. de C.V.**

## Conditions studied

- Severe Acute Respiratory Syndrome Coronavirus 2
- Metabolic Syndrome
- Type 2 Diabetes

## Interventions

- **DRUG:** metformin glycinate
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04626089
- **Lead sponsor:** Laboratorios Silanes S.A. de C.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02
- **Primary completion:** 2021-02
- **Final completion:** 2021-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Administrative decision of the company
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04626089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04626089, "Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04626089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*